The global prostate cancer prevention and treatment market is expected to reach $ 65 billion in 2021, representing an annual growth of 6.6 percent, according to a report from BCC Research Market Forecasting[1]. The market for SpectraCure’s first medical indication alone, recurrent prostate cancer, is very large. Each year, approximately 190,000 patients fall ill in the United States[2]. In Europe, the corresponding figure is about 410,000 patients [3].

After radiation therapy, about 60,000 of these patients suffer from recurrence of prostate cancer, which is initially the target group addressed by SpectraCure. With an estimated revenue of approximately € 35,000 per patient, the potential initial market in the US and the EU is thus worth around SEK 23 billion.

Primary prostate cancer

In addition, there are several possible categories of cancer patients at a later stage, where untreated prostate cancer has great potential, that is, as a direct alternative to radiation and surgery. In cancer care, there is a strong trend to achieve higher quality of life, not just survival. Leading researchers and doctors recommend clinical evaluation of SpectraCure’s method. Few treatment options exist today for patients with recurrent prostate cancer and new methods are in demand in both the US and the EU. This, together with other benefits, such as limited side effects and the possibility of repeating SpectraCure’s treatment if needed, and that the method is suitable as a complement to other treatment, guarantees that the method will be well received.

Initial target market – recurrent prostate cancer

Prostate cancer is the most common cancer in men in the Western world, not at least in the US and the Nordic countries. About 7,3 percent, of just over 1.4 million cases, out of a total of 19 million new cancer cases (worldwide for adult men and women) in 2020, were estimated to be prostate cancer [4].

About 3 million men were estimated to live with prostate cancer in 2016 in the United States [5]. About 9.6 million people died of cancer worldwide in 2018 and approximately 3.8 percent of these deaths were related to prostate cancer.

By comparison, about 2,000 women per year die from breast cancer (6). In Sweden, today there are about 85,000 men who have or have had prostate cancer. The number of diagnosed prostate cancer cases has increased significantly over the past 35 years. The disease is uncommon before the age of 50, but with increasing age the incidence increases. Half of the cases are found in men over 70 years of age.

SpectraCure’s initial target market is patients with relapse after radiotherapy. The reason is that in practice there are only two options, “watchful waiting” or hormone therapy, for this patient group.

Relapses are reported in the order of 20-40 percentage of all treated patients and further radiotherapy is not acceptable, as these tumours are radioresistant and further treatment carries a high risk of radiotherapy-related complications. Cytostatic drugs are not curative and should only be given for late-stage disease relief. Hormone therapy (androgen deprivation) can reduce tumour size and slow down growth, but is not curative and is associated with serious side effects for patients. In the US and the EU, there is a demand for new treatments from the health care system for this category of patients, and the medical need is great.

Given these limitations, there is a strong medical need for new treatments for patients with recurrent prostate cancer. One such approach is interstitial PDT, which is a minimally invasive modality. Interstitial PDT has the potential to provide patients with a significantly better quality of life compared to, for example, hormone therapy.

More indications

In addition to prostate cancer, there are other cancers in, for example, pancreas, head and neck, and breast that can be addressed with SpectraCure’s treatment platform. SpectraCure has initially chosen to focus on patients in reccurent prostate cancer as a commercialization strategy. As the Company has progressed further in demonstrating good effect, PDT has as a first-choice treatment of prostate cancer a great potential. PDT can then be offered as a direct alternative to radiation and surgery, for large patient groups, where traditional therapies are not suitable for example due to the risk of side effects.



[1] BCC Research, “Prevention and Treatment of Prostate Cancer: Technologies and Global Markets”, March 2017.


[3] I diskussion med onkologer och urologer uppskattas andelen lokala återfall i prostatacancer efter strålbehandling till omkring 10% av totala antalet diagnoser i USA. Skattningen är gjord av dr. Keith Cengel, professor i radiologisk onkologi vid University of Pennsylvania, Philadelphia, USA. Validiteten av skattningen har bekräftats av dr. Neil Fleshner, professor i urologi vid University of Toronto och uro- onkolog vid Princess Margaret Cancer Centre i Toronto, Kanada.


[5] (